

ESMO ADVANCED COURSE PROGRAMME
LUNG CANCER IN IMMUNOTHERAPY
A NEW PARADIGM WITH UNANSWERED QUESTIONS

Zürich, Switzerland
3-4 July 2019

CO-CHAIRS: Aurélien Marabelle, France
John Haanen, Netherlands

SPEAKERS: Maurice Pérol, France
Solange Peters, Switzerland
David Planchard, France

LEARNING OBJECTIVES

- Understanding the key players in tumor immunology
- Getting up-to-date on the role of immunotherapy in advanced NSCLC
- The role of biomarkers in selecting NSCLC patients for IT
- Mechanism of combining angiogenesis inhibition with checkpoint inhibition
- Management of IT toxicity and use of IT in specific subgroups of patients

Day 1

09:00-09:10	Welcome and introduction on aims of this course Aurélien Marabelle, FR
9:10-9:40	What every medical oncologist should know about Tumour Immunology John Haanen, NL
09:40-10:40	Session 1 State-of-the-art: Immunotherapy with Immune Check Point Inhibitors of Locally Advanced and Metastatic Non-Small Cell Lung Cancer in 1st and later lines Maurice Pérol, FR
10:40-11:10	Coffee break

- 11:10-11:40 **Debate Pro**
Are all fit patients candidates for 1st-line treatment with Immune Check Point Inhibitors?
YES: one size fits all!
Maurice Pérol, FR
- 11:40-12:10 **Debate Contra**
Are all fit patients candidates for 1st-line treatment with Immune Check Point Inhibitors?
NO: Patients should be selected based on predictive biomarkers
David Planchard, FR
- 12:10-12:30 **Session 4**
In TPS>50%, what is best in 1st-line: single agent Pembrolizumab or CT-IO combination?
Solange Peters, CH
- 12:30-12:45 **Questions and Answers**
- 12:45-13:45 Lunch
- 13:45-14:15 **Session 5**
What is the rationale for adding anti-angiogenics to Immune Check-Points Inhibitors?
Solange Peters, CH
- 14:15-15:00 **Session 6**
Refining patient selection: Immuno-score, -profiling, -gram and Tumor Mutation Burden
The point of view of the Immunologist
John Haanen, NL
- 15:00-15:45 **Session 7**
Efficacy evaluation of Immune Check Points Inhibitors: Recist 1.1, iRecist or Ir Recist?
The issue and risk of hyper-progression
Brain metastasis as a target
Aurélien Marabelle, FR
- 15:45-16:00 **Questions and Answers**
- 16:00-16:30 Coffee break
- 16:30-17:15 **Session 8**
Toxicity issues with Immune Check Points inhibitors
John Haanen, NL
- 17:15-17:45 Use of checkpoint inhibitors in patients with AID and chronic viral infections
Aurelien Marabelle, FR
- 17:45-18:00 **Questions and Answers**
- 19:00 Networking dinner

Day 2

9:00-12:30

Workshop sessions

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotation basis)

15' Introduction based on clinical cases presented by speakers

35' Discussion

10' Break

Workshop 1

When to stop immunotherapy or treatment beyond progression

Aurélien Marabelle, FR

Workshop 2

Choosing treatment based on biomarkers

Solange Peters, CH

David Planchard, FR

11:00-11:30

Coffee break

Workshop 3

Managing toxicity

John Haanen, NL

12:30-13:15

Feedback on the workshops from each group

13:15-13:30

Synthesis and wrap-up

Aurélien Marabelle, FR

John Haanen, NL

13:30-14:30

Lunch